Liquiritin attenuates pathological cardiac hypertrophy by activating the pka/lkb1/ampk pathway

HIGHLIGHTS

  • who: Liquiritin Attenuates Pathological and collaborators from the Department of Cardiology, Renmin Hospital of Wuhan University, Wuhan, China, Hubei Key Laboratory of Metabolic and have published the article: Liquiritin Attenuates Pathological Cardiac Hypertrophy by Activating the PKA/LKB1/AMPK Pathway, in the Journal: (JOURNAL)
  • what: To test this hypothesis, in this study the authors evaluated the effects of LQ in a mouse model of pressure overload-induced cardiac hypertrophy induced by aortic banding (AB). Since LQ increased cardiomyocyte cAMP levels, and LQ-mediated LKB1 phosphorylation was prevented after PKA inhibition, the authors propose that LQ . . .

     

    Logo ScioWire Beta black

    If you want to have access to all the content you need to log in!

    Thanks :)

    If you don't have an account, you can create one here.

     

Scroll to Top

Add A Knowledge Base Question !

+ = Verify Human or Spambot ?